drugset / Trial / NCT01211808

Effect of Diltiazem on Pharmacokinetics of BMS-914392

NCT01211808

Phase 1 Completed 24 enrolled Bristol-Myers Squibb PRA Health Sciences · collab
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to assess the effects of diltiazem on the pharmacokinetics of single-dose BMS-914392 in healthy subjects.

Timeline

Start
2010-09
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-914832 Unknown 30 mg Oral
Subject Diltiazem Small molecule 360 mg Oral

Indications